An observational study in Tricuspid Regurgitation and Pacemaker, sponsored by Haiyan Wang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by Haiyan Wang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.
Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 19th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
Jiangsu Trulive Medical Co., Ltd · Sites in China
Ages 65+
Shanghai Huihe Medical Technology Co., Ltd · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
First Hospital of China Medical University · Sites in China
Ages 18+
Hangzhou Valgen Medtech Co., Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 129 across the 16 interventional studies, 2,320 across the 12 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 28 have an industry lead sponsor. The 10 most frequent:
Haiyan Wang is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Haiyan Wang has 1 study filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Tricuspid Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT05595187Nanjing Medical UniversityConcomitant Tricuspid Repair in Patients With Left Heart Surgery | 2026-12-31 |
| NCT05194423Changhai HospitalTHE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein | 2027-03 |
| NCT06663566Beijing Anzhen HospitalApplication of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.
This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.
This retrospective study analyzed patients undergoing pacemaker implantation from January 2015 to March 2025, stratified by pacing modality (right ventricular/conduction system/biventricular pacing) and TR progression (worsened [≥1-grade increase] vs non-worsened TR).
The protocol included: (1) 3D echocardiographic assessment of TR mechanisms, (2) quantitative fluoroscopic analysis of lead parameters (tension, mobility, angulation), (3) multivariable regression evaluating pacing modes and TR progression on clinical outcomes, and (4) documentation of device-related complications (lead dislodgement/infection) and heart failure rehospitalization.
Patients after cardiac pacemaker implantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Pacemaker implantation
Device: Pacemaker implantation
Device: Pacemaker implantation
Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing
Tricuspid regurgitation progression(Progression of tricuspid regurgitation ≥ grade 0.5)
Grading of tricuspid regurgitation severity:Grade 0: None Grade 0.5: Trace Grade 1: Mild Grade 1.5: Mild to moderate Grade 2: Moderate Grade 2.5: Moderate to severe Grade 3: Severe
Time frame: Mean follow-up of 1 year
Heart Failure Readmission Rate After CIED Implantation
Time frame: Mean follow-up of 1 year
Plan to share: No
Start is estimated for Apr 2025; primary completion for Mar 2026, 11 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →
Haiyan Wang